Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154335 · ClinicalTrials.gov registry record · Phase 1
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01154335 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 18 participants.
The verdict
NCT01154335, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.
Interventions
- DRUG Everolimus
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154335
The ClinicalTrials.gov registry entry for NCT01154335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01154335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154335 about?
NCT01154335 is a clinical study titled "Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer". The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.
What is the current status of trial NCT01154335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01154335?
The interventions under investigation include: Everolimus (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01154335?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.